With all the bad news about AAPL it will implode.
There are several articles out there talking about the end of AAPL as it comes to an end of the cycle.
Sentiment: Strong Sell
I now believe that AMGN can hit 150 before the end of the year. I think AMGN has a real potential for hitting 150 in two to three month...
Sentiment: Strong Buy
Gilead going red just means one thing, that market makers need new shares before they can take it higher. Otherwise they don't have enough shares and can't make money. They need to pay off their summer house in the Hamptons and the Ferrari.
I've maintained rather larger positions in GILD and BIIB as well. With price targets around 140 for Gilead and an outstanding quarter I'd say lightening strikes twice could be possible. I've also positions in AMGN and ALXN. It seem bio-tech in general is doing well today.
Sentiment: Strong Buy
Up 12 % after a good quarter.
If that would happen to Gilead it could hit 100 running tomorrow...
Not specific to Gilead, one of my largest investment, but about that the market in general. According to Graham we have a few hundred point to go on the S&P to get to the bubble territory...
"WALL STREET'S BEST MINDS
GMO'S Jeremy Grantham Doesn't See a Bubble Just Yet
The famed investor says the economy's "early-cycle look" is best reason why a big stock decline is not imminent.
By JEREMY GRANTHAM
Updated July 18, 2014 4:50 p.m. ET
Editor's Note: Grantham is founder of GMO, a Boston-based money manager. This is an excerpt of his latest quarterly market commentary. The full version of this piece, is available on the GMO Website.
Despite a shocking 2.9% setback in first quarter GDP (quarterly decline at annualized rate), the extent of which was forecast by no one, and despite a substantial decline in NIPA corporate earnings, the market has climbed slowly but steadily in recent months. Market volatility has declined to very low levels despite these setbacks and despite Middle Eastern problems.
(The negative January Rule this year has, for that matter, also been ineffective so far.) So, all is apparently well, as we have arrived within three months of the dreaded (by bears) presidential third year. Accordingly, my recent forecast of a fully-fledged bubble, our definition of which requires at least 2250 on the S&P, remains in effect.
In early July, Janet Yellen made an admirably clear statement that she is sticking faithfully to the Greenspan-Bernanke policy of extreme moral hazard. She will not use interest rates to head off or curtail any asset bubbles encouraged by the extremely low rates that might appear. And history is clear: very low rates absolutely will encourage extreme speculation. But Yellen will, as Greenspan and Bernanke before her, attempt to limit only the damage any breaking bubbles might cause. Well, it is a clear policy and in my opinion clearly wrong. I had thought that central bankers by now, after so much unnecessary pain, might have begun to
That really should boost stock price over a hundred over the next few days....
Barrons: "Gilead Sciences: Time For a Dividend?"
"By Ben Levisohn
Nomura’s N. Ian Somaiya has a bunch of nice things to say about Gilead Sciences (GILD) yesterday, but the most interesting bit might be his expectation that Gilead initiates a dividend next year:
We raise our TP on Gilead Sciences to $141, from $130, on strength of prescription data for Sovaldi and our assumptions for peak sales of $22bn (up from $16bn)based on launch of new two-drug and three-drug HCV combos in 2017 and 2018, respectively. We expect Phase I/II data by year end (potentially AASLD Nov 7-11) to confirm their ability to maintain cure rates above 90%, while reducing treatment duration to six weeks. Our revised estimates are based on avg price per patient of $70k, below Sovaldi’s $84k and payor expectations for combination prices of $120-150k. Our revised model strengthens our view that Gilead Sciences is the most attractively priced large-cap growth stock in the healthcare industry, with 2015 P/E of 11.2x. With free cash flow expected to reach ~$8.8bn in 2014 and ~$13bn in 2015, we believe Gilead Sciences will not only continue to aggressively buy back shares but also introduce a dividend in 2015.
Big biotech stocks have been strong today, and none more so than Gilead Sciences. Its shares have jumped 3.6% to $88.15% at 12:35 p.m. today, while Celgene (CELG) has risen 2.6% to $85.31, Regeneron (REGN) has advanced 2,2% to $302.78, Biogen Idec (BIIB) has gained 1.3% to $303.04 and Amgen (AMGN) is up 2% at 117.65."
Not published and not widely known I think one of concern is about the 1.3 million affected inmates. If everyone is requesting the treatment than our government would be out a lot of money all at once vs, a gradual spent with some inmates being released, etc..
Just wondering what the thoughts are about timing of AMGN hitting 150.
Earnings announcement will on 7/29 after close with consensus at $2.07. Whisper number is $2.16. If the whisper number is confirmed and AMGN is reporting solid numbers than it could hit 150 by end of year.
Sentiment: Strong Buy
BIIB will announce blow out earnings 4/21....